W

Wei Peng Yong

National University of Singapore

ORCID: 0000-0003-4404-3777

496 papers and 14.7k citations.

PubIndex Score71Top 29% · seniorHow it's scored

496Publications

14.7kTotal Citations

First publication: 2001First senior author: 2006

Top publicationsby citations

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle, Ghassan K. Abou‐Alfa, S. Tanasanvimon et al.|The Lancet. Gastroenterology & hepatology|2021

Cited by 423

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor

Vinod Vijay Subhash, Wei Peng Yong|Scientific Reports|2018

Cited by 105

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.

Milind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|Journal of Clinical Oncology|2021

Cited by 86

Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression

Foong Ying Wong, Wei Peng Yong|PLoS ONE|2012

Cited by 38

Polydopamine-Coated Radiolabeled Microspheres for Combinatorial Radioembolization and Photothermal Cancer Therapy

Manran Wu, Mingyuan Gao, Lei Zhang et al.|ACS Applied Materials & Interfaces|2023

Cited by 37

Indexing the rest of 496 publications…